文献速递中医内科中药与中成药合理使用

附子理中丸通过下调PI3K/AKT/NF-κB通路抑制DSS诱导溃疡性结肠炎小鼠炎症并促进结肠黏膜愈合

Fuzi Lizhong Pill inhibited inflammatory response and promoted colon mucosal healing in dextran sulfate sodium-induced ulcerative colitis mice by down-regulating PI3K/AKT/NF-κB signaling pathway.
PubMed 文献 · J Ethnopharmacol · 2025-02-11

本研究以DSS诱导的溃疡性结肠炎小鼠为模型,评估附子理中丸的治疗效果及机制。结果发现附子理中丸可缓解临床症状、降低DAI评分、逆转脾肿大和胸腺萎缩、改善血液学指标,并抑制TNF-α和IL-6表达、促进紧密连接蛋白表达和结肠上皮细胞增殖。机制可能通过下调PI3K/Akt/NF-κB信号通路抑制炎症反应并修复结肠黏膜屏障。

要点

  • 附子理中丸可缓解DSS诱导UC小鼠的体重下降、便血和稀便等症状。
  • 附子理中丸抑制TNF-α和IL-6表达,促进ZO-1、Occludin和Claudin 1表达。
  • 机制可能与下调PI3K/Akt/NF-κB信号通路有关。

核心结论

  • 附子理中丸可能通过下调PI3K/Akt/NF-κB信号通路抑制炎症反应并修复结肠黏膜屏障,从而治疗溃疡性结肠炎。

研究设计与样本

  • 采用UPLC-Q-Orbitrap HRMS鉴定附子理中丸化学成分,并建立DSS诱导的溃疡性结肠炎小鼠模型进行体内外实验。

主要发现

  • 附子理中丸中鉴定出99种化合物,包括生物碱、香豆素和黄酮类。
  • 附子理中丸缓解UC小鼠体重下降、便血和稀便等临床症状,显著降低DAI评分。
  • 附子理中丸显著逆转DSS引起的脾肿大和胸腺萎缩,改善出血和炎症相关血液学指标。
  • 体外和离体研究显示附子理中丸抑制TNF-α和IL-6表达,促进紧密连接蛋白ZO-1、Occludin和Claudin 1表达,并促进结肠上皮细胞增殖。
  • 附子理中丸抑制PI3K、Akt和NF-κB基因转录水平及相关蛋白表达或磷酸化水平。

临床怎么用

  • 对于中医辨证属虚寒证的溃疡性结肠炎患者,可考虑使用附子理中丸辅助治疗。
  • 临床应用需结合患者具体证候,并关注其抗炎和黏膜修复作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Fuzi Lizhong Pill (FLP), a traditional Chinese herbal formula, has been historically used for treating gastrointestinal disorders characterized by cold deficiency patterns. Its application in ulcerative colitis (UC) stems from its warming and tonifying properties. AIM OF THE STUDY: To evaluate the efficacy of FLP in the treatment of UC and investigate its mechanism of action. MATERIALS AND METHODS: The chemical constituents of FLP were identified using UPLC-Q-Orbitrap HRMS. By establishing a preclinical UC mouse model with DSS and treating with FLP, we evaluated the effect of FLP on UC mice in terms of clinical symptoms, physiological indices, and histopathological examination. The anti-inflammatory and mucosal repair effects of FLP were examined at three levels: cellular, organoid, and animal, using immunohistochemistry, western blotting, RT-PCR, and other techniques. RESULTS: We characterized the chemical composition of FLP and identified 99 compounds, including alkaloids, coumarins, and flavonoids. In UC mice, FLP alleviated clinical symptoms such as weight loss, blood in stools, and loose stools in UC mice; significantly reduced DAI scores in UC mice; significantly reversed splenomegaly and thymic atrophy caused by DSS; improved hemorrhage and inflammation-related hematological indices. In vitro and ex vivo studies showed that FLP inhibited the expression of TNF-α and IL-6, promoted the expression of the tight junction proteins ZO-1, Occludin, and Claudin 1, and promoted the proliferation of colonic epithelial cells in vivo. FLP also inhibited the transcription levels of PI3K, Akt, and NF-κB genes, as well as the expression or phosphorylation levels of related proteins in vitro and in vivo. CONCLUSION: FLP may play a role in the treatment of UC by inhibiting the inflammatory response and repairing the colonic mucosal barrier by downregulating the PI3K/Akt/NF-κB signaling pathway.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Li Y, Tian Y, Zhu L, et al. Fuzi Lizhong Pill inhibited inflammatory response and promoted colon mucosal healing in dextran sulfate sodium-induced ulcerative colitis mice by down-regulating PI3K/AKT/NF-κB signaling pathway. J Ethnopharmacol. 2025. PMID: 39947366. doi:10.1016/j.jep.2025.119483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。